Guangwei Du1, Tian Liu2, Mechelle M Lewis1,3, Lan Kong4, Yi Wang5, James Connor6, Richard B Mailman1,3, Xuemei Huang1,3,6,7,8. 1. Department of Neurology, Penn State University-Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States. 2. MedImageMetric LLC, New York, New York, United States. 3. Department of Pharmacology, Penn State University-Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States. 4. Department of Public Health Sciences, Penn State University-Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States. 5. Department of Radiology, Weill Cornell Medical College, New York, New York, United States. 6. Department of Neurosurgery, Penn State University-Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States. 7. Department of Radiology, Penn State University-Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States. 8. Department of Kinesiology, Penn State University-Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States.
Abstract
BACKGROUND: Parkinson's disease (PD) is marked pathologically by dopamine neuron loss and iron overload in the substantia nigra pars compacta. Midbrain iron content is reported to be increased in PD based on magnetic resonance imaging (MRI) R2* changes. Because quantitative susceptibility mapping is a novel MRI approach to measure iron content, we compared it with R2* for assessing midbrain changes in PD. METHODS: Quantitative susceptibility mapping and R2* maps were obtained from 47 PD patients and 47 healthy controls. Midbrain susceptibility and R2* values were analyzed by using both voxel-based and region-of-interest approaches in normalized space, and analyzed along with clinical data, including disease duration, Unified Parkinson's Disease Rating Scale (UPDRS) I, II, and III subscores, and levodopa-equivalent daily dosage. All studies were done while PD patients were "on drug." RESULTS: Compared with controls, PD patients showed significantly increased susceptibility values in both right (cluster size = 106 mm(3)) and left (164 mm(3)) midbrain, located ventrolateral to the red nucleus that corresponded to the substantia nigra pars compacta. Susceptibility values in this region were correlated significantly with disease duration, UPDRS II, and levodopa-equivalent daily dosage. Conversely, R2* was increased significantly only in a much smaller region (62 mm(3)) of the left lateral substantia nigra pars compacta and was not significantly correlated with clinical parameters. CONCLUSION: The use of quantitative susceptibility mapping demonstrated marked nigral changes that correlated with clinical PD status more sensitively than R2*. These data suggest that quantitative susceptibility mapping may be a superior imaging biomarker to R2* for estimating brain iron levels in PD.
BACKGROUND:Parkinson's disease (PD) is marked pathologically by dopamine neuron loss and iron overload in the substantia nigra pars compacta. Midbrain iron content is reported to be increased in PD based on magnetic resonance imaging (MRI) R2* changes. Because quantitative susceptibility mapping is a novel MRI approach to measure iron content, we compared it with R2* for assessing midbrain changes in PD. METHODS: Quantitative susceptibility mapping and R2* maps were obtained from 47 PDpatients and 47 healthy controls. Midbrain susceptibility and R2* values were analyzed by using both voxel-based and region-of-interest approaches in normalized space, and analyzed along with clinical data, including disease duration, Unified Parkinson's Disease Rating Scale (UPDRS) I, II, and III subscores, and levodopa-equivalent daily dosage. All studies were done while PDpatients were "on drug." RESULTS: Compared with controls, PDpatients showed significantly increased susceptibility values in both right (cluster size = 106 mm(3)) and left (164 mm(3)) midbrain, located ventrolateral to the red nucleus that corresponded to the substantia nigra pars compacta. Susceptibility values in this region were correlated significantly with disease duration, UPDRS II, and levodopa-equivalent daily dosage. Conversely, R2* was increased significantly only in a much smaller region (62 mm(3)) of the left lateral substantia nigra pars compacta and was not significantly correlated with clinical parameters. CONCLUSION: The use of quantitative susceptibility mapping demonstrated marked nigral changes that correlated with clinical PD status more sensitively than R2*. These data suggest that quantitative susceptibility mapping may be a superior imaging biomarker to R2* for estimating brain iron levels in PD.
Authors: Ashley K Lotfipour; Samuel Wharton; Stefan T Schwarz; V Gontu; Andreas Schäfer; Andrew M Peters; Richard W Bowtell; Dorothee P Auer; Penny A Gowland; Nin P S Bajaj Journal: J Magn Reson Imaging Date: 2011-10-10 Impact factor: 4.813
Authors: E Mark Haacke; Norman Y C Cheng; Michael J House; Qiang Liu; Jaladhar Neelavalli; Robert J Ogg; Asadullah Khan; Muhammad Ayaz; Wolff Kirsch; Andre Obenaus Journal: Magn Reson Imaging Date: 2005-01 Impact factor: 2.546
Authors: Sotirios A Parashos; Sheng Luo; Kevin M Biglan; Ivan Bodis-Wollner; Bo He; Grace S Liang; G Webster Ross; Barbara C Tilley; Lisa M Shulman Journal: JAMA Neurol Date: 2014-06 Impact factor: 18.302
Authors: Madaline B Harrison; Scott A Wylie; Robert C Frysinger; James T Patrie; Diane S Huss; Lillian J Currie; G Frederick Wooten Journal: Mov Disord Date: 2009-01-30 Impact factor: 10.338
Authors: Ramin Jafari; Sujit Sheth; Pascal Spincemaille; Thanh D Nguyen; Martin R Prince; Yan Wen; Yihao Guo; Kofi Deh; Zhe Liu; Daniel Margolis; Gary M Brittenham; Andrea S Kierans; Yi Wang Journal: J Magn Reson Imaging Date: 2019-01-13 Impact factor: 4.813
Authors: Ernest W Wang; Guangwei Du; Mechelle M Lewis; Eun-Young Lee; Sol De Jesus; Sangam Kanekar; Lan Kong; Xuemei Huang Journal: Neurobiol Aging Date: 2019-01-16 Impact factor: 4.673
Authors: Guangwei Du; Mechelle M Lewis; Christopher Sica; Lu He; James R Connor; Lan Kong; Richard B Mailman; Xuemei Huang Journal: Mov Disord Date: 2018-05-14 Impact factor: 10.338